YU FAN

Ms. YU FAN

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2024 in ACS Sustainable Chemistry & Engineering
Verified
Journal Article
Closed access
YFYi-Lin Fan
Yi-Lin Fan
HZHeng-Fan Zhao
Heng-Fan Zhao
JWJi-Xiang Wang
Ji-Xiang Wang
WLWen-Hui Li
Wen-Hui Li
FWFeng Wei
Feng Wei
GZGeng Zhang
Geng Zhang

Verified
Journal Article
Open access
PDF file
YFYU FAN
YU FAN
SCShuo Cong
Shuo Cong
EYEn Ping Yap
En Ping Yap
DHDerek Hausenloy
Derek Hausenloy
CRChrishan J Ramachandra
Chrishan J Ramachandra
Ischemic heart disease (IHD) is the leading cause of heart failure (HF) and is a significant cause of morbidity and mortality globally. An ischemic event induces cardiomyocyte death, and the ability for the adult heart to repair itself is challenged by the limited proliferative capacity of resident cardiomyocytes. Intriguingly, changes in metabolic substrate utilisation at birth coincide with the terminal differentiation and reduced proliferation of cardiomyocytes, which argues for a role of cardiac metabolism in heart regeneration. As such, strategies aimed at modulating this metabolism-proliferation axis could, in theory, promote heart regeneration in the setting of IHD. However, the lack of mechanistic understanding of these cellular processes has made it challenging to develop therapeutic modalities that can effectively promote regeneration. Here, we review the role of metabolic substrates and mitochondria in heart regeneration, and discuss potential targets aimed at promoting cardiomyocyte cell cycle re-entry. While advances in cardiovascular therapies have reduced IHD-related deaths, this has resulted in a substantial increase in HF cases. A comprehensive understanding of the interplay between cardiac metabolism and heart regeneration could facilitate the discovery of novel therapeutic targets to repair the damaged heart and reduce risk of HF in patients with IHD.